Damian O'Connell

Damian O'Connell serves as the Chief Executive Officer of the Experimental Drug Development Centre (EDDC) since September 2018, overseeing a national platform dedicated to drug and biomarker discovery and early clinical development. In addition to this role, Damian O'Connell contributes as a Scientific Advisory Board Member at BluMaiden Biosciences and as a member of multiple advisory and expert panels, including the Singapore Translational Cancer Consortium and SingHealth's Investigational Medicine Unit. An Adjunct Professor at University College Cork and a Board Member of the INFANT Research Centre, Damian O'Connell has previously held senior positions at Bayer, Pfizer, and Molecular Medicine Ireland. With an educational background that includes a PhD in Physiology and Pharmacology and a Doctor of Medicine from University College Cork, along with advanced executive education from Harvard Business School, Damian O'Connell has a strong foundation in both clinical research and drug development.